Midterm - Clinical Trials Flashcards

1
Q

What are the Prentice Criteria for establishing valid surrogates?

A
  • Treatment affects surrogate
  • Surrogate predicts clinical event/ endpoint
  • Surrogate fully captures treatment’s effect on the clinical event/ endpoint
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are 2 ways AEs are evaluated?

A
  • Severity
  • Relatedness to study drug/ intervention
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are 3 of 5 criteria for AE to be classified as serious adverse event (SAE)?

A

Event leads to
* death
* hospitalization/ prolonging of existing hospitalization
* disability/ incapacity that’s persistent/ significant
* congenital abnormalities/ birth defects

Or event is life-threatening

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is a SUSAR and how is a SUSAR related to other AEs?

A
  • Suspected: The event is possibly connected to the study drug/ intervention.
  • Unexpected: Event is not included on investigator brochure/ approved drug label.
  • Severe: SUSARs are a SAE subtype.
  • Adverse
  • Reaction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the benefits & challenges associated with composite endpoints?

A

BENEFITS
* Potentially more holistic metric
* Larger sample size (i.e. more events)

CHALLENGES
* Components of composite usually vary in severity
and in impact on quality of life. This muddies interpretation.
* Time to event analyses usually focus on 1st event
and ignore multiple events of the same or different
types.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are two approaches to co-primary endpoint analysis and the tradeoffs of each approach?

A

Two approaches:
1) Require both endpoints achieve a specific level of
significance for the new treatment to be considered a success (i.e. p < 0.05 for all endpoints)
* Does not inflate type-I error rate
* reduces power

2) Require either endpoint to reach a specific
significance level for the treatment to be considered a success (i.e. p < 0.05 for one co-primary endpoint)
* Inflates type-I error rate (multiple comparison correction needed to control type-I error rate)
* maintains power

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the advantages and disadvantages of simple and permuted block randomization?

A

SR:
* Pro: Easy to do, straightforward inference and theoretical analysis.
* Con: Can have chance imbalance in allocation ratio.

PBR:
* Pro: Ensures balanced allocation ratio, and balances against bias from changing participant characteristics.
* Con: Slightly more difficult to implement/ analyze. Also, if the block size is discovered by participant/ provider, unblinding is possible.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What’s a pro and a con of using broad inclusion criteria in clinical trials?

A

Pro: Recruitment easier. Potentially increased generalizability.

Con: Treatment effect might be specific to subgroup(s), so broad inclusion criteria might dilute such an effect.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Define and give an example of single blind design.

A

D: Patient is blinded to treatment whereas provider is unblinded.

e.g. surgeon is aware of medical device settings, but patient is not.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Define and give an example of confounding variable.

A

D: Variable that impacts independent variable (treatment) and dependent variable (endpoint), potentially causing spurious associations.

e.g. coffee drinkers might smoke more cigarettes than non-coffee drinkers. Smoking might act as a confounder in a study of the association between coffee drinking and heart disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Does simple randomization (SR)/ permuted block randomization (PBR) have an advantage in the following contexts:
* Allocation concealment in a non-blind study
* Loss of power due to treatment total imbalance
* Changing patient characteristics over time.

A

SR wins for allocation concealment in a non-blind study since, in PBR, if the size is discovered, providers can anticipate which treatment is to be given next and preferentially enroll certain patients.

PBR wins for
* Loss of power due to treatment total imbalance
* Changing patient characteristics over time.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What randomization method is used to create a pre-stratification randomization schedule? What’s the goal of this randomization method?

A

Stratified randomization:
1. Stratify
2. Randomize to treatment.

Goal: Balance with respect to prognostic factors.

(This is distinct from permuted block randomization where the goal is to achieve balance with respect to treatment arm over time)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Give 2 advantages of pre-stratification.

A
  • Prevents “accidental bias” resulting from maldistribution of important prognostic variables
  • Increases precision (if stratifying variables are
    related to outcome)
  • Ensures balance on stratifying factors in early
    interim analyses (even in large trials)
  • Facilitates subgroup analysis by stratifyng factor (more optimal allocation ratio)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the primary disadvantage of pre-stratification?

A

Logistics involved in implementing several randomization schedules.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe intention-to-treat (ITT) and per protocol (PP) analysis in 1-2 sentences.

A

Intention-to-treat (ITT) analysis includes all randomized participants in the groups to which they were originally assigned, regardless of whether they completed the intervention according to the study protocol.

Per protocol (PP) analysis, on the other hand, includes only those participants who completed the intervention exactly as planned.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Give pro and con of each analysis approach, intention-to-treat (ITT) and per protocol (PP).

A

ITT
* Pro: Maintains the benefits of randomization.
* Con: Might dilute treatment effect by including participants that didn’t actually receive the treatment under study.

PP
* Pro: Potentially provides a more accurate measure of the treatment’s effectiveness
* Con: Risk introducing bias due to non-random loss of participants.

17
Q

Bias: Excluding patients who did not qualify for a study vs. excluding patients from the analysis who did not take their assigned treatment as planned.

A
  • Excluding patients who did not qualify helps ensure the study population is homogenous and relevant to the research question, potentially reducing confounding but may limit the generalizability of the results.
  • Excluding patients from the analysis who did not take their assigned treatment as planned can introduce bias by violating the random allocation process, potentially leading to overestimation or underestimation of the treatment effect.
18
Q

Checklists vs. open-ended questionnaires for AE reporting..?

A
  • Checklists: Standardized data collection
  • Open-ended: Unexpected responses allowed.
19
Q

Give pro and con of double-blinded relative to unblinded.

A

Pro: Control for placebo effect/ subjective reporting of endpoints/ AEs. Provider differential treatment of subjects is also controlled for.

Con: Admin burden.

20
Q

Blinding treatment assignment vs. allocation concealment

A

Blinding: Practice of concealing treatment assignment post-assignment is meant to alleviate performance bias and detection bias.

Allocation concealment: Meant to prevent selection bias on enrolling participants since subsequent assignments aren’t available.

21
Q

Factors to consider when determining to use pre-stratification or not

A
  • Size of study
  • Homogeneity of subjects
  • Prognostic factor strength
  • Admin burden
  • Credibility
22
Q

Why might post-stratification be used even if no baseline difference exists between two treatment groups?

A
  • Increased precision
  • Subgroup inference
  • Potentially account for interactions between treatment & prognostic factors, increasing generalizability
23
Q

Define fixed allocation randomization scheme.

A

Probability of treatment assignment constant throughout study.

24
Q

Define adaptive allocation randomization scheme.

A

Probability of treatment assignment changes throughout study in response to covariates/ outcomes.

25
Q

How would sample size of trial influence recommendation to implement stratified design/ not?

A

Smaller: Stratify against fewer factors & consider PBR. If extremely small, small block size required.

Bigger: Ok to stratify on more factors/ levels. Larger block size/ even simple randomization fine though I generally don’t prefer SR since it doesn’t balance changing participant characteristic over time.

26
Q

What are common RCT designs?

A

Parallel Designs
* Factorial designs
* Cluster randomized designs

Crossover Designs

27
Q

What’s the hierarchy of evidence in clinical research?

A
  1. RCT
  2. Prospective follow-up studies
  3. Case-control studies
  4. Cross-sectional studies
  5. Uncontrolled trials of an intervention
  6. Case histories
    * Individual cases
    * Case series
  7. Chance observations